Strides Pharma ScienceNSE:STAR +0.04%67 Return-on-Tangible-Equity is 29.63% as of Mar. 2026, which is 78% above its 10-year median of 16.62. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹776.38 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 898 Drug Manufacturers companies, Strides Pharma Science ranks better than 88.75% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Strides Pharma Science's annualized net income for the quarter that ended in Mar. 2026 was ₹5,078 Mil. Strides Pharma Science's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹17,135 Mil. Therefore, Strides Pharma Science's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 29.63%.
The historical rank and industry rank for Strides Pharma Science's Return-on-Tangible-Equity or its related term are showing as below:
NSE:STAR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -31.46 Med: 16.62 Max: 24498.32
Current: 35.8
During the past 13 years, Strides Pharma Science's highest Return-on-Tangible-Equity was 24,498.32%. The lowest was -31.46%. And the median was 16.62%.
NSE:STAR's Return-on-Tangible-Equity is ranked better than 88.75% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs NSE:STAR: 35.80
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Strides Pharma Science Return-on-Tangible-Equity Related Terms
Strides Pharma Science Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Strides Pharma Science's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:STAR vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 29.63% mean?
Strides Pharma Science (NSE:STAR) has a Return-on-Tangible-Equity of 29.63% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Strides Pharma Science and its competitors. This is 78% above median its historical median of 16.62. According to the industry distribution chart, Strides Pharma Science ranks #101 out of 898 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is Strides Pharma Science's Return-on-Tangible-Equity too high?
Strides Pharma Science's current Return-on-Tangible-Equity of 29.63% is 78% above median its 10-year median of 16.62. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Strides Pharma Science's value of 29.63% is 276% above this industry median. Based on the distribution chart, Strides Pharma Science ranks #101 out of 898 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #101 out of 898 companies for Return-on-Tangible-Equity. This places Strides Pharma Science in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.88. Strides Pharma Science's value of 29.63% is 276% above this benchmark. While the company's 10-year median is 16.62 vs. the industry median of 7.88, Strides Pharma Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current Return-on-Tangible-Equity of 29.63% is 276% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Return-on-Tangible-Equity is 29.63%, which is 78% above median its own 10-year median of 16.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹776.38, compared to a current price of ₹1,126.80 — trading 45.1% above its estimated fair value. The current Return-on-Tangible-Equity is 29.63%, which is 78% above median its 10-year median of 16.62 and 276% above the Drug Manufacturers industry median of 7.88. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Return-on-Tangible-Equity is 29.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,126.80 is trading 45.1% above its estimated GF Value™ of ₹776.38.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Return-on-Tangible-Equity: 29.63% (78% above median its 10-year median of 16.62)
GF Value™: ₹776.38 vs. price of ₹1,126.80 (45.1% above fair value)
Industry Position: 276% above the Drug Manufacturers median (#101 of 898)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score
Get the complete analysis for NSE:STAR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
